

Supplementary Table 3. Lipid profiles at follow-up in the modified intention-to-treat population

	ROS10/EZT10 (n=273)	ROS20 (n=257)	P
LDL-C (mg/dL)	57.4±24.6	66.3±26.2	<0.0001
Total-C (mg/dL)	118.6±29.5	128.9±29.3	<0.0001
Triglyceride (mg/dL)	108.6±52.7	117.5±57.6	0.0933
HDL-C (mg/dL)	47.7±12.4	48.1±11.3	0.6184

Data are presented as mean±standard deviation.
LDL-C, low-density lipoprotein cholesterol; Total-C, total cholesterol; HDL-C, high-density lipoprotein cholesterol.

Supplementary Table 4. End points in the per-protocol population

End points	ROS10/EZT10 (n=262)	ROS20 (n=237)	Odds ratio (95% confidence interval)	P
Primary end point				
LDL-C reduction ≥50%	193 (73.7)	140 (59.1)	1.938 (1.328–2.827)	0.0006
Secondary end points				
LDL-C <70 mg/dL	214 (81.7)	160 (67.5)	2.146 (1.417–3.248)	0.0003
LDL-C reduction ≥50% or LDL-C <70 mg/dL	225 (85.9)	180 (75.9)	1.926 (1.218–3.044)	0.0046
Absolute LDL-C reduction (mg/dL)	73.6±36.7	66.1±32.9	-	0.0174
LDL-C reduction percentage (%)	54.6±20.5	49.4±17.7	-	0.0025
Multiple lipid goal achievement	191 (72.9)	130 (54.9)	2.214 (1.524–3.217)	<0.0001
Major vascular events	1 (0.4)	9 (3.8)	0.097 (0.012–0.772)	0.0081
All death	0 (0)	1 (0.4)	0.508 (0.046–5.632)	0.2926
New onset diabetes	8 (4.4)	7 (4.1)	1.058 (0.375–2.984)	0.9145
Rhabdomyolysis	0 (0)	0 (0)	-	>0.9999
Fatigue Severity Scale	14.4±9.6	13.8±8.2	-	0.4610
Significant liver enzyme elevation*	5 (1.9)	0 (0)	5.535 (0.662–46.31)	0.0326

Data are presented as mean±standard deviation or n (%).
LDL-C, low-density lipoprotein cholesterol.
*Significant liver enzyme elevation: alanine aminotransferase or aspartate aminotransferase elevation >3 times from baseline.

Supplementary Table 5. LDL-C related endpoints after excluding patients who discontinued study medications transiently or permanently between the 1st follow-up visit (at day 30) and the final visit (at day 90)

Endpoints	ROS10/EZT10 (n=269)	ROS20 (n=247)	Odds ratio (95% confidence interval)	P
Primary endpoint				
LDL-C reduction ≥50%	197 (73.2)	143 (58.7)	1.925 (1.329–2.787)	0.0005
Secondary endpoints				
LDL-C <70 mg/dL	217 (80.7)	163 (66.0)	2.151 (1.440–3.212)	0.0002
LDL-C reduction ≥50% or LDL-C <70 mg/dL	228 (84.8)	183 (74.1)	1.945 (1.255–3.013)	0.0026
Absolute LDL-C reduction (mg/dL)	73.2±36.9	69.8±35.1	-	0.0236
LDL-C reduction percentage	54.2±21.0	48.9±19.6	-	0.0028

Data are presented as n (%) or mean±standard deviation.
LDL-C, low-density lipoprotein cholesterol.